EGFR and head and neck cancer: To assess the degree to which dacomitinib and cetuximab block EGFR signaling in head and neck cancer cell lines and ascertain if its effectiveness in blocking EGFR is associated with their ability to inhibit growth, we performed Western blot analysis to assess protein levels and phosphorylation status of key molecules in the EGFR signaling pathway.